Business Context and Reporting Period
This Form 8-K was filed by Hancock Jaffe Laboratories, Inc. (HJLI) on April 24, 2020. The report details a material definitive agreement entered into on the same date to raise capital through a registered direct offering and a concurrent private placement. Note: The request metadata referenced "Envveno Medical Corp," but the filing text explicitly identifies the registrant as Hancock Jaffe Laboratories, Inc.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $1.0 million.
- Securities Issued: 1,886,793 shares of Common Stock and warrants to purchase an equal number of shares (1,886,793 Warrant Shares).
- Pricing: Common Stock at $0.405 per share; Warrants at $0.125 per warrant (combined price of $0.53).
- Warrant Terms: Immediately exercisable at $0.405 per share; expire five years from issuance.
- Net Proceeds: Expected to be approximately $825,786 after deducting placement agent fees and expenses, excluding potential warrant exercise proceeds.
- Placement Agent Fees: 8.0% cash fee of gross proceeds, plus an 8% warrant fee and up to $55,000 in expense reimbursement.
Material Changes
The filing represents a significant capital raise event. The company entered into a Securities Purchase Agreement to sell equity and warrants. The closing of the transaction is expected on or about April 28, 2020. This transaction increases the company's share count and introduces new warrant obligations.
Guidance, Outlook, and Use of Proceeds
The Company intends to use the net proceeds from the transactions for working capital and general corporate purposes. No specific financial guidance or forward-looking revenue projections were provided in this filing. The offering was priced at the market under Nasdaq rules.
Investor Verification Checklist
- Verify the closing date of the transaction (expected April 28, 2020) and confirm receipt of funds.
- Review the impact of the 1,886,793 new shares and warrants on existing shareholder dilution.
- Confirm the total cash fees paid to Spartan Capital Securities, LLC (8% of gross proceeds).
- Check subsequent filings for the actual net proceeds received versus the estimated $825,786.
- Monitor the exercise of warrants, which could provide additional capital at $0.405 per share.